Quantbot Technologies LP Has $26,000 Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

Quantbot Technologies LP lessened its stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) by 80.8% during the 4th quarter, HoldingsChannel reports. The firm owned 1,106 shares of the company’s stock after selling 4,667 shares during the quarter. Quantbot Technologies LP’s holdings in OrthoPediatrics were worth $26,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP boosted its stake in OrthoPediatrics by 16.2% during the 3rd quarter. Wellington Management Group LLP now owns 883,221 shares of the company’s stock valued at $23,944,000 after purchasing an additional 122,846 shares during the period. State Street Corp grew its stake in shares of OrthoPediatrics by 1.0% in the third quarter. State Street Corp now owns 417,898 shares of the company’s stock worth $11,329,000 after acquiring an additional 4,236 shares during the last quarter. Geode Capital Management LLC increased its position in OrthoPediatrics by 2.1% during the third quarter. Geode Capital Management LLC now owns 391,492 shares of the company’s stock worth $10,615,000 after acquiring an additional 7,972 shares during the period. Portolan Capital Management LLC raised its stake in OrthoPediatrics by 66.2% during the 3rd quarter. Portolan Capital Management LLC now owns 308,099 shares of the company’s stock valued at $8,353,000 after purchasing an additional 122,770 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its stake in OrthoPediatrics by 1.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 251,588 shares of the company’s stock valued at $5,832,000 after purchasing an additional 4,728 shares during the last quarter. Institutional investors own 69.05% of the company’s stock.

Wall Street Analysts Forecast Growth

KIDS has been the subject of a number of research analyst reports. Stifel Nicolaus cut their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Needham & Company LLC reissued a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a report on Wednesday, March 5th. Finally, Truist Financial cut their target price on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th.

OrthoPediatrics Price Performance

OrthoPediatrics stock opened at $25.05 on Wednesday. The business has a 50 day simple moving average of $24.70 and a 200 day simple moving average of $25.16. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The company has a market capitalization of $608.39 million, a PE ratio of -20.37 and a beta of 1.22. OrthoPediatrics Corp. has a one year low of $21.02 and a one year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The firm had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. During the same period in the previous year, the business earned ($0.23) earnings per share. On average, sell-side analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO David R. Bailey sold 6,620 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares of the company’s stock, valued at $7,934,193.30. The trade was a 2.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $132,006.60. Following the sale, the general counsel now directly owns 110,767 shares in the company, valued at $2,753,667.62. The trade was a 4.57 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 23,732 shares of company stock valued at $589,978. 31.80% of the stock is currently owned by insiders.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.